Answers are grounded in this paper and cite their sources.
Observational findings reveal aspirin improves limb and cardiovascular outcomes in individuals with diabetic foot disease and peripheral arterial disease, implying its utility for prevention.
Among diabetic patients with PAD and a history of a foot event, aspirin was associated with comparable limb and cardiovascular outcomes, and potentially favorable survival, compared with clopidogrel or cilostazol. These observational findings suggest aspirin is a practical antiplatelet option for secondary prevention in this high-risk population, though further precise trials are needed to verify.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: